B
셀레스트라
352770KOSDAQ62.3 / 100
Reference Date: 2026-09-08
Financial Score29.5 / 40
News Sentiment18.8 / 25
Momentum10.0 / 20
Disclosure4.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Celestera develops and commercializes services for early disease diagnosis using genome-based biohealth information processing, liquid biopsy platforms, cancer diagnostics, and multi-omics technologies. Key products include Geno-Test, CD-Prime, and Cancer-Prime, with a dedicated bio big data center for research and commercialization.
Number of Employees
11people
Average Salary
85.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
—Industry Average 1.203.5Point
ROE
3157.50Industry Average 8.007.0Point
394.7x industry avg (excellent)
Debt Ratio
-10.65Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20257.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼50.9% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲45.0% (2-year basis)
ROE Trend
4.0 / 4
Avg ROE 951.3% (improving, 3yr)
Detailed News Sentiment
2 totalPositive 1Neutral 0Negative 1Average Sentiment Score 75
- Negative셀레스트라, 회생계획안 못내고 결국 절차 폐지…신규 투자 유치 난항
셀레스트라는 회생계획안 미제출로 인해 수원회생법원에 의해 회생절차가 폐지되어 기업 재건에 어려움을 겪고 있다.
- Positive셀레스트라, 회생절차 폐지 결정…"신규 투자자 확보 후 재신청 검토....
셀레스트라는 회생절차 폐지 결정으로 재무 부담 완화 및 신규 투자자 유치 가능성이 높아져 긍정적 영향 기대.
Detailed Momentum
52-week position4.0Point
52w mid range (50%)
Current 5,250Won52-week high 5,25052-week low 5,250
1-month return3.0Point
1m 0% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
6 totalPositive 0Neutral 4Negative 2
- Negative기타시장안내 (회생절차 폐지결정 관련 시장조치 미진행)2026-08-24
- Negative회생절차폐지결정2026-08-24
- Neutral반기또는분기매출액미달사실발생2026-08-14
- Neutral기타시장안내 (상장적격성 실질심사 사유 추가 관련 절차 미진행)2026-08-14
- Neutral반기보고서 (2026.06)2026-08-14